Diazyme Laboratories, Inc.

Home
United States
Poway, CA
Diazyme Laboratories, Inc.

Diazyme is a clinical chemistry reagent manufacturer that develops IVD assays for use on conventional open channel automated chemistry platforms.

09/01/2026

September is Sepsis Awareness Month

Sepsis affects millions of lives every year, often progressing rapidly and unpredictably. Early detection is critical to improving outcomes. At Diazyme Laboratories, we’re committed to supporting healthcare professionals in the fight against sepsis with our Procalcitonin (PCT) Assay, designed for rapid, reliable diagnosis.

Why PCT? Procalcitonin is a powerful biomarker that helps clinicians detect bacterial infections and monitor the severity of sepsis. Our PCT Assay delivers timely, accurate results, giving providers the insights they need to make informed, life-saving decisions.

Let’s raise awareness and empower our healthcare community with the tools they need to combat sepsis head-on.
Together, we can make a difference. Join us in recognizing and learn more about how Diazyme’s PCT Assay can support early diagnosis and improved patient care.

Learn more here: https://bit.ly/4hS0IxY

08/31/2026

Diazyme’s Lipoprotein(a) Molarity Assay provides quantitative measurement of Lp(a) in molar units (nmol/L), offering a standardized approach to Lp(a) measurement.

FDA 510(k) cleared and designed for convenient laboratory use with liquid-stable reagents.

Learn more about Diazyme’s Lp(a) Molarity Assay --> https://bit.ly/4qKvhYP

08/27/2026

Innovating Diagnostics, Advancing Healthcare 🔬

At Diazyme, we are dedicated to developing innovative enzyme-based technologies that help clinical laboratories deliver high quality, cost effective diagnostic testing.
Our comprehensive menu of assays spans key areas such as cardiovascular disease, oncology, diabetes, inflammation, infectious disease, and more. We support laboratories with flexible solutions designed for use on most major clinical chemistry analyzers.

What sets Diazyme apart:
• Innovative enzyme-based technologies
• Comprehensive diagnostic panels
• High-quality, cost-effective solutions
• Commitment to advancing patient care

By partnering with laboratories around the world, Diazyme aims to make advanced diagnostics more accessible, efficient, and impactful for the patients they serve.
Learn more about Diazyme’s diagnostic solutions:

🔗 https://bit.ly/36lKaaV

08/24/2026

Support kidney stone risk assessment with Diazyme’s Oxalate Enzymatic Assay 🧪🧬

Oxalate is a common component in urine originating from liver metabolism and dietary sources. The formation of calcium oxalate salts in the urinary tract is a key factor in urolithiasis, and urine oxalate testing provides valuable information related to hyperoxaluria and stone formation risk.

Diazyme’s Oxalate Enzymatic Assay is a cost effective, reliable method for the quantitative determination of oxalate in human 24 hour urine samples. Utilizing industry standard enzymatic chemistry with oxalate oxidase and colorimetric detection at 550 nm, the assay delivers high analytical sensitivity and robust performance for routine clinical use.

Key advantages include:
• Enzymatic assay for accurate determination of oxalate in urine samples
• Wide analytic measuring range: 0.011–4.0 mmol/L (0.099–36.0 mg/dL)
• Liquid stable, ready to use reagents; calibrator and controls offered separately for added convenience
• Demonstrated precision with total CV typically ≤6.6%

Regulatory status: 510(k) Exempt.
For in vitro diagnostic use.

Learn more about Diazyme’s Oxalate Enzymatic Assay and how it can support your lab’s kidney stone–related testing:
🔗 https://bit.ly/4wh4mF9

08/20/2026

Confidently support multiple myeloma testing with Diazyme’s Human Kappa (κ) and Lambda (λ) Free Light Chain (KLFLC) assays 🧬🔬

Diazyme’s KLFLC assays provide accurate and reliable measurement of free light chains in human serum, correlating well with current methods and supporting the diagnosis and monitoring of multiple myeloma in conjunction with other laboratory findings.

Key advantages include:
• Excellent precision and a large dynamic measuring range
• Liquid stable format with no reagent preparation, helping reduce sample handling
• No sample pre dilution required, with reduced manual dilutions and retesting
• Fast test results (approximately 10 minutes) for rapid turnaround time

510(k) Cleared; Health Canada Registered.

Learn more about how Diazyme’s KLFLC assays can support your lab’s plasma cell disorder testing:

Kappa Free Light Chain Assay:
🔗 https://bit.ly/45d0vOk

Lambda Free Light Chain Assay:
🔗 https://bit.ly/3TDQuat

08/18/2026

Looking Beyond Traditional Lipid Testing

Cardiovascular risk assessment goes beyond LDL cholesterol alone. Complementary biomarkers can provide additional insights into lipid burden, oxidative stress, inherited risk, and vascular inflammation.
In this carousel, we highlight four important cardiovascular biomarkers:

LDL-C – Measures LDL cholesterol, a foundational marker of lipid assessment.

OxLDL – Reflects oxidative modification of LDL associated with oxidative stress.

Lp(a) – A genetically determined lipoprotein associated with increased cardiovascular risk.

PLAC® (Lp-PLA₂ Activity) – Measures Lp-PLA₂ activity associated with vascular inflammation.

Together, these biomarkers provide a more comprehensive view of cardiovascular risk than traditional lipid testing alone.

Learn more about Diazyme's cardiovascular marker portfolio:
https://bit.ly/4q7YFbg

08/13/2026

Advancing Cardiovascular Insight with Diazyme’s Advanced Lipid Profiling 🫀🔬

Cardiovascular disease remains a significant global health challenge, and standard cholesterol testing alone may not fully reflect an individual’s true risk. Diazyme’s cardiovascular markers portfolio is designed to provide a more complete view of cardiovascular health by assessing lipoproteins, oxidative changes, and vascular inflammation.

By incorporating advanced lipid and vascular biomarkers, Diazyme’s assays help:
• Characterize atherogenic lipoproteins beyond routine LDL and HDL
• Evaluate oxidative modification of lipids linked to plaque development
• Assess vascular inflammation and plaque activity associated with cardiovascular events
• Identify residual cardiovascular risk that may persist despite controlled traditional lipids

Designed for use on automated chemistry analyzers, Diazyme’s cardiovascular markers integrate smoothly into existing laboratory workflows, supporting high-throughput, reliable testing for both clinical and research applications.

Discover how Diazyme’s advanced lipid profiling and cardiovascular biomarker portfolio can enhance your cardiovascular testing and research programs:
🔗 https://bit.ly/4q7YFbg

08/10/2026

ADLM 2026 Recap: Thank You, Anaheim

ADLM 2026 in Anaheim was an energizing week for the Diazyme team! We were grateful for the chance to meet with so many laboratory and diagnostics professionals, share our latest developments, and hear directly from the people using our solutions every day.

Throughout the meeting, our booth was a hub for:
• Demonstrations of Diazyme’s specialty assays and analyzer solutions
• Conversations about workflow efficiency, assay performance, and future needs
• New connections and renewed partnerships across the clinical diagnostics community

To everyone who visited, asked questions, or explored new ways to collaborate with Diazyme, we appreciate your engagement and insights. Your feedback helps guide our ongoing work to deliver innovative, accessible diagnostic solutions for laboratories worldwide.

Want to continue the conversation or learn more?
🔗 https://bit.ly/4wbso48

07/27/2026

🎉 ADLM 2026 kicks off tomorrow!

We’re ready to meet you, share what’s new at Diazyme, and dive into the future of diagnostics together.

📍 Visit Booth #1923 and follow us for daily show highlights!

Reserve a meeting here: https://bit.ly/3SEnq1V

07/24/2026

We're excited to share that Cincinnati Children's Hospital Medical Center will present a poster featuring the clinical validation of the Diazyme MMP-7 Assay as a non-invasive screening tool to help rule out biliary atresia in newborns and infants.

• Poster: A-347
• Tuesday, July 28, 2026
• 1:30 – 2:30 pm

The presentation highlights the assay's analytical performance and its potential to support efficient, cost-effective screening in clinical laboratories.

We look forward to seeing you at ADLM 2026! Learn more: https://bit.ly/4yAA1DO

Address

12889 Gregg Court
Poway, CA
92064

Website

http://www.diazyme.com/

Alerts

Be the first to know and let us send you an email when Diazyme Laboratories, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Business in Poway?